CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are both peptide compounds evaluated on Vial: CJC-1295 is available as a compounded preparation with clinical-trial evidence, and Ipamorelin is available as a compounded preparation with clinical-trial evidence, offered by 16 and 20 verified providers respectively.
Vial summary · compiled from public records
At a glance
Side by side
| Field | CJC-1295 | Ipamorelin |
|---|---|---|
| Category | Peptide | Peptide |
| Brand names | — | — |
| FDA / legal status | Compoundable | Compoundable |
| Evidence tier | Clinical Trials | Clinical Trials |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | Available through 503A and 503B compounding pharmacies | Available through 503A and 503B compounding pharmacies |
| Providers on Vial | 16 listed | 20 listed |
| Typical price band | $$ to $$$ | $$ to $$$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
About Ipamorelin
A synthetic pentapeptide growth hormone secretagogue, ipamorelin selectively stimulates pituitary release of growth hormone by mimicking ghrelin and binding to the growth hormone secretagogue receptor (GHS-R). Unlike earlier secretagogues, it demonstrates high selectivity for GH release with minimal effect on cortisol, prolactin, or appetite-regulating hormones. Research applications have focused on its potential use in growth hormone deficiency, age-related muscle loss, and bone metabolism studies.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.